产时B族链球菌预防与儿童过敏性疾病
该回顾性队列研究纳入14 046名儿童,评估母亲产时接受B族链球菌(GBS)抗生素预防是否增加子代5岁内哮喘、湿疹、食物过敏或过敏性鼻炎风险。结果显示,GBS预防与复合过敏结局及各项过敏结局均无显著关联,按分娩方式分层结果一致。
要点
- 产时GBS抗生素预防未增加子代5岁内哮喘、湿疹或食物过敏的复合结局风险。
- 按阴道分娩和剖宫产分层,GBS预防与复合过敏结局均无显著关联。
- 哮喘、湿疹、食物过敏及过敏性鼻炎单独分析亦未显示与GBS预防相关。
核心结论
- 产时GBS抗生素预防与子代5岁内哮喘、湿疹、食物过敏或过敏性鼻炎的诊断无显著关联。
研究设计与样本
- 回顾性队列研究,纳入14 046名儿童。
- GBS预防定义为母亲在分娩前至少4小时静脉给予青霉素、氨苄西林、头孢唑林、克林霉素或万古霉素。
- 复合主要结局为5岁内诊断哮喘、湿疹或食物过敏,并需相应药物处方;过敏性鼻炎仅用诊断代码定义并单独分析。
- 分析按分娩方式预先分层,采用Cox比例风险模型校正多变量;二次分析限5岁时仍留在队列的儿童,采用多因素logistic回归。
主要发现
- 阴道分娩儿中,GBS预防与复合结局风险无显著关联(HR 1.13,95%CI 0.95-1.33)。
- 剖宫产儿中,GBS预防与复合结局风险无显著关联(HR 1.08,95%CI 0.88-1.32)。
- 5岁时留在队列的10 404名儿童中,阴道分娩儿GBS预防与复合结局无显著关联(OR 1.21,95%CI 0.96-1.52)。
- 5岁时留在队列的10 404名儿童中,剖宫产儿GBS预防与复合结局无显著关联(OR 1.17,95%CI 0.88-1.56)。
- 哮喘、湿疹、食物过敏单独分析及过敏性鼻炎均与GBS预防无显著关联。
临床怎么用
- 对于接受产时GBS抗生素预防的母亲,可告知其子代5岁内过敏性疾病风险未见显著增加,无需因过敏担忧而改变GBS预防决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if maternal intrapartum group B Streptococcus (GBS) antibiotic prophylaxis is associated with increased risk of childhood asthma, eczema, food allergy, or allergic rhinitis. METHODS: Retrospective cohort study of 14 046 children. GBS prophylaxis was defined as administration of intravenous penicillin, ampicillin, cefazolin, clindamycin, or vancomycin to the mother, ≥4 hours before delivery. Composite primary outcome was asthma, eczema, or food allergy diagnosis within 5 years of age, identified by diagnosis codes and appropriate medication prescription. Allergic rhinitis was defined by using diagnostic codes only and analyzed as a separate outcome. Analysis was a priori stratified by delivery mode and conducted by using Cox proportional hazards model adjusted for multiple confounders and covariates. Secondary analyses, restricted to children retained in cohort at 5 years' age, were conducted by using multivariate logistic regression. RESULTS: GBS prophylaxis was not associated with increased incidence of composite outcome among infants delivered vaginally (hazard ratio: 1.13, 95% confidence interval [CI]: 0.95-1.33) or by cesarean delivery (hazard ratio: 1.08, 95% CI: 0.88-1.32). At 5 years of age, among 10 404 children retained in the study, GBS prophylaxis was not associated with the composite outcome in vaginal (odds ratio: 1.21, 95% CI: 0.96-1.52) or cesarean delivery (odds ratio: 1.17, 95% CI: 0.88-1.56) cohorts. Outcomes of asthma, eczema, food allergy, separately, and allergic rhinitis were also not associated with GBS prophylaxis. CONCLUSIONS: Intrapartum GBS prophylaxis was not associated with subsequent diagnosis of asthma, eczema, food allergy, or allergic rhinitis in the first 5 years of age.
引用
- Dhudasia MB, Spergel JM, Puopolo KM, et al. Intrapartum Group B Streptococcal Prophylaxis and Childhood Allergic Disorders. Pediatrics. 2021. PMID: 33833072. doi:10.1542/peds.2020-012187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。